GLP-1 Drugs May Reduce Brain Pressure, Headaches, and Vision Loss in Intracranial Hypertension

Systematic review and meta-analysis following PRISMA guidelines. Researchers searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Library through July 2025. Seven studies with 11,973 total participants were included. Random-effects models pooled relative risks (RRs) and standardized mean differences (SMDs) for IIH outcomes.

Idiopathic intracranial hypertension causes debilitating headaches and can lead to permanent vision loss. Current treatments are limited. This meta-analysis provides the strongest evidence to date that GLP-1 drugs — already widely used for diabetes and weight loss — could be repurposed to treat this challenging neurological condition, potentially preventing blindness in affected patients.

This adds to the rapidly growing list of conditions where GLP-1 drugs show unexpected benefits beyond diabetes and obesity. If confirmed in randomized controlled trials, GLP-1 agonists could become a first-line treatment for IIH — a condition that currently has limited options and can cause irreversible blindness. The fact that benefits occurred without significant weight loss suggests GLP-1 may directly affect cerebrospinal fluid dynamics or intracranial pressure through mechanisms we don't yet fully understand.

Most included studies were likely observational rather than randomized controlled trials, which limits causal conclusions. The non-significant improvement in objective visual measurements (despite reduced papilledema and blindness risk) is puzzling and may reflect measurement timing or sensitivity issues. The non-significant BMI change raises questions about the mechanism of action in IIH.